The treated natural history of high risk superficial bladder cancer: 15- year outcome

Journal of Urology

Volumn 158, Issue 1, 1997, Pages 62-67

  Cookson, Michael S ^a,b   Herr, Harry W ^a   Zhang, Zuo Feng ^a   Soloway, Scott ^a   Sogani, Pramod C ^a   Fair, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

BCG vaccine; Bladder neoplasms; carcinoma in situ

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DOSE RESPONSE; HIGH RISK PATIENT; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION;

EID: 0030914050     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199707000-00017     Document Type: Article

References (27)

1. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116: 180, 1976.
2. Lamm, D. L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. N. Amer., 19: 573, 1992.
3. Herr, H. W., Laudone, V. P. and Whitmore, W. F., Jr.: An overview of intravesical therapy for superficial bladder tumors. J. Urol., 138: 1363, 1987.
4. Herr H. W.: Uncertainty, stage and outcome of invasive bladder cancer. J. Urol., 152: 401, 1994.
5. Lamm, D. L., Riggs, D. R., Traynelis, C. L. and Nseyo, U. O.: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol., 153: 1444, 1995.
6. Pinsky, C. M., Camacho, F. J., Kerr, D., Geller, N. L., Klein, F. A., Herr, H. A., Whitmore, W. F., Jr. and Oettgen, H. F.: Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat. Rep., 69: 47, 1985.
7. Herr, H. W., Wartinger, D. D., Fair, W. R. and Oettgen, H. F.: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J. Urol., 147: 1020, 1992.
8. Herr H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., Jr. and Oettgen, H. F.: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol., 13: 1404, 1995.
9. Heney, N. M.: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol. Clin. N. Amer., 19: 429, 1992.
10. Herr, H. W., Jakse, G. and Sheinfeld, J.: The T1 bladder tumor. Sem. Urol., 8: 254, 1990.
11. Lamm, D. L.: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol., 134: 40, 1985.
12. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D. and Garbeglio, A.: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol., 146: 32, 1991.
13. Melekos, M. D., Chionis, H., Pantazakos, A., Fokaefs, E., Paranychianakis, G. and Dauaher, H.: Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of controlled prospective trial with modified treatment schedule. J. Urol., 149: 744, 1993.
14. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Jr., Sullivan, J., Sarosdy, M. F., Crissman, J. D. and Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl. J. Med., 325: 1205, 1991.
15. Martínez-Piñeiro, J. A., León, J. J., Martínez-Piñeiro, L., Jr., Fiter, L., Mosteiro, J. A., Navarro, J., Matres, M. J. G. and Cárcamo, P.: Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol., 143: 502, 1990.
16. Jauhianen, K., Rintala, E., Alfthan, O. and the Finnbladder Group: Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer. In: Immunotherapy of Urological Tumours. Edited by J. B. deKernion and E. Mazema. New York: Churchill Livingstone, pp. 13-60, 1990.
17. Witjes, J. A., van der Meijden, A. P. M., Witjes, W. P., Doesburg W., Schaafsma, H. E. and Debruyne, F. M. J.: A randomized prospective study comparing intravesical instillations of mitomycin C, BCG-Tice, and BCG-RIVM in PTa, PT1 tumors and primary CIS of the urinary bladder. Eur. J. Cancer, 29A: 1672, 1993.
18. Rübben, H., Graf-Dobberstein, C., Ostwald, R., Stauffenberg, A., Jaeger, N., Deutz, F. J., Steffens, L. and Giani, G.: Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer; mitomycin C vs BCG Connaught vs TUR alone. In: Immunotherapy of Urological Tumours. Edited by J. B. deKernion and E. Mazema. New York: Churchill Livingstone, chapt. 3, pp. 27-36, 1990.
19. Brosman, S. A.: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J. Urol., 128: 27, 1982.
20. Debruyne, F. M. J., van der Meijden, A. P. M., Geboers, A. D., Franssen, M. P., van Leeuwen, M. J., Steerenberg, P. A., de Jong, W. H. and Ruitenberg, J. J.: BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized, prospective trial. Urology, suppl., 31: 20, 1988.
21. Herr, H. W., Laudone, V. P., Badalament, R. A., Oettgen, H. F., Sogani, P. L., Freedman, B. D., Melamed, M. R. and Whitmore, W. F., Jr.: BCG therapy alters the progression of superficial bladder cancer. J. Clin. Oncol., 6: 1450, 1988.
22. Amling, C. L., Thrasher, J. B., Frazier, H. A., Dodge, R. K., Robertson, J. E. and Paulson, D. F.: Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J. Urol., 151: 31, 1994.
23. Malkowicz, S. B., Nichols, P., Lieskovsky, G., Boyd, S. D., Huffman, J. and Skinner, D. G.: The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J. Urol., 144: 641, 1990.
24. Siref, L. E. and Zincke, H.: Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Urology, 31: 309, 1988.
25. Pagano F., Bassi, P., Galetti, T. P., Meneghini, A., Milani, C., Artibani, W. and Garbeglio, A.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J. Urol., 145: 45, 1991
26. Schwalb, D. M., Herr, H. W., Sogani, P. C., Russo, P., Sheinfeld, J. and Fair, W. R.: Upper tract disease following intravesical BCG for superficial bladder cancer: five year follow-up. J. Urol., part 2, 147: 273A, abstract 237, 1992.
27. Miller, E. B., Eure, G. R. and Schellhammer, P. F.: Upper tract transitional cell carcinoma following treatment for superficial bladder cancer with BCG. Urology, 42: 26, 1993.